Full-Time

Associate Director

Regulatory Affairs

Posted on 1/24/2026

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$146.7k - $196.7k/yr

+ Annual Bonus + Incentive Compensation + Equity Awards

Remote in USA

Remote

Category
Legal & Compliance (1)
Requirements
  • Bachelors degree required; advanced degree preferred
  • 8+ years of experience in the biotechnical or pharmaceutical industry, and a minimum of 5 years experience in a Regulatory capacity
  • Experience working as a lead in Regulatory Affairs with the FDA is preferred
  • Prior experience with small molecules and biologics is preferred
  • Thorough understanding of drug development process and the pharmaceutical industry and healthcare environment including regulatory requirements and policy trends
  • Extensive regulatory experience with INDs/CTAs, NDAs/BLAs, lifecycle management, interactions with Health Authorities, leading and managing regulatory teams, developing and implementing regulatory strategies with a proven track record of significant regulatory accomplishments
  • Strong business acumen and ability to make sound decisions that contribute positively to the business
  • Very strong strategic skills including creativity and effectiveness in identifying and addressing major strategic challenges and the ability to balance short-term needs with long-term vision
  • Proven ability to deliver on goals within a cross-functional team/partnership environment with a high level of professionalism
  • Excellent verbal and written skills; Able to analyze, define and effectively convey difficult and complex issues to internal and external stakeholders
  • Skilled in conflict resolution/negotiation; fosters open communication; listens and facilitates discussion
  • Strong negotiating skills and ability to think creatively and develop creative solutions
  • Proven ability to build trust and respect within the organization
  • Ability to prioritize and handle multiple projects simultaneously
  • Interacts with external business partners and Regulatory Agencies
Responsibilities
  • Provides high level regulatory strategic and operational direction for North America and mentorship on projects including, but not limited to general regulatory strategies, regulatory requirements for clinical studies and marketing approval, regulatory strategic development plans and risk assessments, critical issue management and advice for the FDA and Health Canada interactions
  • Uses extensive knowledge of US regulatory requirements and applies this knowledge both strategically and operationally to development projects and marketed product regulatory issues to support corporate goals
  • Oversees the preparation and submission of documentation to support investigational and marketing registration packages within the US and Canada ensuring timelines are met in alignment with the global strategy as determined by the global regulatory leader
  • Reviews sections of the documents that will be utilized in the US and Canada in support of clinical trials and marketing applications, and their amendments in conformance with local regulatory requirements
  • Liaises and negotiates with the FDA and Health Canada as needed for all aspects pertaining to drug development including resolution of key regulatory issues and to expedite approvals of product and labeling changes
  • Maintains awareness of global regulatory environment and assess impact of changes on business and product development programs. Facilitate policy and development of standard interpretation of global regulation
  • Integrates functional expertise with business knowledge to solve problems and make good decisions for the overall business
  • Trains, develops, and manages an effective regional regulatory team both via direct and indirect reporting structure
  • Builds partnerships with senior key stakeholders from other functions to ensure that strategic business goals are met through the sharing of knowledge and expertise
  • Manages critical issues, taking leadership for the regulatory contribution
  • Responsible for assisting with the development and implementation of regulatory processes
  • Recruits, develops, manages, and mentors regulatory professionals and helps create a goal-oriented culture
  • Some supervisory responsibilities for multi-level regulatory team(s)
  • Travel: 10-20% as required
Desired Qualifications
  • 8+ years of experience in the biotechnical or pharmaceutical industry, and a minimum of 5 years experience in a Regulatory capacity with a broad background
  • Lead experience in Regulatory Affairs with the FDA is preferred
  • Experience with small molecule and biologics
  • Excellent communication and collaboration skills at senior stakeholder levels
  • Global regulatory affairs experience and cross-functional leadership

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Brukinsa generated $1.1 billion in first-quarter 2026 sales, up 38%.
  • Sonrotoclax won FDA accelerated approval for relapsed or refractory mantle cell lymphoma.
  • TEVIMBRA plus ZIIHERA holds FDA Priority Review for HER2-positive gastric cancer.

What critics are saying

  • Revenue remains heavily dependent on Brukinsa, exposing BeOne to competitive erosion.
  • Sonrotoclax's approval depends on CELESTIAL-RRMCL confirmatory results.
  • TEVIMBRA diversification is unproven, with revenue still trailing Brukinsa materially.

What makes BeOne unique

  • BeOne combines Brukinsa, Tevimbra, and sonrotoclax across blood and solid tumors.
  • Its global trial network spans 30,000 patients and 75 approval markets.
  • Brukinsa remains the only BTK inhibitor with head-to-head PFS superiority.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at BeOne who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

-16%

1 year growth

-19%

2 year growth

-13%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...

INACTIVE